Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: Results from the international ONE registry

Haemophilia

Volumn 19, Issue 4, 2013, Pages 571-577

  Chambost, H ^a,b   Santagostino, E ^c   Laffan, M ^d   Kavakli, K ^e  

^a TIMONE HOSPITAL   (France)

^b INSERM   (France)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Bleeding; Dose; Haemophilia; Inhibitors; Recombinant factor VIIa; Registry

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIIA; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HUMANS; INTERNATIONALITY; RECOMBINANT PROTEINS; REGISTRIES; TREATMENT OUTCOME;

EID: 84879461542     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12140     Document Type: Article

References (17)

1. NovoSeven® EU. Summary of product characteristics (SmPC). Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdf. Accessed June 3, 2011.
2. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in hemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
3. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
4. Parameswaran R, Shapiro AD, Gill JC, Kessler CM, the HTRS Registry. Dose effect and efficacy of rFVIIa in the treatment of hemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
5. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of haemoarthroses in haemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
6. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G, for the NovoSeven Trial (F7HAEM-1510) Investigators. Home treatment of haemoarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. Thromb Haemost 2006; 95: 600-5.
7. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
8. Salek SZ, Benson GM, Elezović I et al. The need for speed in the management of haemophilia patients with inhibitors. Haemophilia 2011; 17: 95-102.
9. Auerswald G, Muntean W, Kemkes-Matthes B et al. Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts] [Article in German. Hamostaseologie 2009; 29: 197-203.
10. Shapiro A. Single-dose recombinant activated Factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. Clin Adv Hematol Oncol 2008; 6: 579-86.
11. Berntorp E, Collins P, D'Oiron R et al. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. Haemophilia 2011; 17: e202-10.
12. Puetz J. Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients. Drug Del Devel Ther 2010; 4: 127-37.
13. Chambost H. A prospective, observational, post-approval registry of inhibitor patients treated with multiple or single doses of recombinant activated factor VII. Semin Hematol 2008; 45: S35-7.
14. Salaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752-9.
15. Santagostino E, Morfini M, Auerswald GK et al. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia 2009; 15: 983-9.
16. Lusher J, Roberts H, Davignin et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998; 4: 790-8.
17. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiencies of factor VIII or IX with inhibitors. Haemophilia 2008; 14: 898-909.